Dexcom Inc. Stock
Dexcom Inc. Stock
We can see a decrease in the price for Dexcom Inc.. Compared to yesterday it has lost -€1.400 (-1.150%).
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Dexcom Inc..
As a result the target price of 136 € shows a slightly positive potential of 12.55% compared to the current price of 120.84 € for Dexcom Inc..
For the coming years our community has positive and negative things to say abot the Dexcom Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Dexcom Inc. | -1.150% | 2.476% | -1.532% | 11.455% | 7.931% | 77.055% | 359.380% |
Dentsply Sirona Inc. | -1.460% | 0.502% | -9.081% | -30.027% | -19.111% | -53.133% | -46.649% |
Teleflex Inc. | -0.990% | 8.021% | 4.124% | -11.404% | -10.619% | -37.267% | - |
Baxter International | 1.070% | -2.068% | -12.417% | -18.480% | -7.432% | -52.174% | -52.350% |
Comments
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at Raymond James from $151.00 to $160.00. They now have a "strong-buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at UBS Group AG from $153.00 to $163.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at Citigroup Inc. from $148.00 to $161.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily
DexCom (DXCM) Q1 2024 Earnings Call Transcript
Dexcom Reports First Quarter 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.
First Quarter 2024 Financial Highlights:
-
Revenue grew 24% year-over-year to